Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled master protocol of HRS-4729 and HRS9531 in adults with MASH
CTR20262382Phase 2Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Aug 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-4729, HRS9531 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Fujian Shengdi Pharmaceuticals. Started Aug 2026; status: active.
02
Drugs
HRS-4729HRS9531
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20262382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262382.